Difference between revisions of "Template:GABA receptor modulators"
Jump to navigation
Jump to search
imported>Zakblade2000 |
imported>Dr Curious m |
||
| (5 intermediate revisions by 4 users not shown) | |||
| Line 16: | Line 16: | ||
* [[Bamaluzole]] | * [[Bamaluzole]] | ||
* [[Barbiturate]]s (e.g., [[phenobarbital]])<!--At high concentrations--> | * [[Barbiturate]]s (e.g., [[phenobarbital]])<!--At high concentrations--> | ||
| + | * [[Beta-Alanine]] | ||
* [[BL-1020]] | * [[BL-1020]] | ||
* [[5-Aminovaleric acid|DAVA]] | * [[5-Aminovaleric acid|DAVA]] | ||
| Line 31: | Line 32: | ||
* [[Isonipecotic acid]] | * [[Isonipecotic acid]] | ||
* [[Kojic amine]] | * [[Kojic amine]] | ||
| + | * [[L-838,417]] | ||
* [[Lignan]]s (e.g., [[honokiol]]) | * [[Lignan]]s (e.g., [[honokiol]]) | ||
* [[Methylglyoxal]] | * [[Methylglyoxal]] | ||
| Line 46: | Line 48: | ||
* [[Quisqualamine]] | * [[Quisqualamine]] | ||
* [[SL-75102]] | * [[SL-75102]] | ||
| + | * [[Taurine]] | ||
* [[trans-4-Aminocrotonic acid|TACA]] | * [[trans-4-Aminocrotonic acid|TACA]] | ||
* [[trans-2-(Aminomethyl)cyclopropanecarboxylic acid|TAMP]] | * [[trans-2-(Aminomethyl)cyclopropanecarboxylic acid|TAMP]] | ||
| Line 54: | Line 57: | ||
* ''Positive modulators (abridged; see [[Template:GABAAR PAMs|here]] for a full list):'' [[α-Ethyl-α-methylthiobutyrolactone|α-EMTBL]] | * ''Positive modulators (abridged; see [[Template:GABAAR PAMs|here]] for a full list):'' [[α-Ethyl-α-methylthiobutyrolactone|α-EMTBL]] | ||
| − | * [[Alcohol]]s (e.g., [[ | + | * [[Alcohol]]s (e.g., [[alcohol (drug)|drinking alcohol]], [[tert-Amyl alcohol|2M2B]]) |
* [[Anabolic steroid]]s | * [[Anabolic steroid]]s | ||
* [[Avermectin]]s (e.g., [[ivermectin]]) | * [[Avermectin]]s (e.g., [[ivermectin]]) | ||
| Line 77: | Line 80: | ||
* [[Loreclezole]] | * [[Loreclezole]] | ||
* [[Monastrol]] | * [[Monastrol]] | ||
| − | * [[Neuroactive steroid]]s (e.g., [[allopregnanolone]], [[cholesterol]]) | + | * [[Neuroactive steroid]]s (e.g., [[allopregnanolone]], [[cholesterol]], [[THDOC]]) |
* [[Niacin]] | * [[Niacin]] | ||
* [[Nicotinamide|Nicotinamide (niacinamide)]] | * [[Nicotinamide|Nicotinamide (niacinamide)]] | ||
| Line 153: | Line 156: | ||
* [[Flurothyl]] | * [[Flurothyl]] | ||
* [[Furosemide]] | * [[Furosemide]] | ||
| + | * [[Golexanolone]] | ||
* [[Iomazenil (123I)|Iomazenil (<sup>123</sup>I)]] | * [[Iomazenil (123I)|Iomazenil (<sup>123</sup>I)]] | ||
* [[IPTBO]] | * [[IPTBO]] | ||
Latest revision as of 15:45, 6 March 2020
Initial visibility: currently defaults to autocollapse
To set this template's initial visibility, the |state= parameter may be used:
|state=collapsed:{{GABA receptor modulators|state=collapsed}}to show the template collapsed, i.e., hidden apart from its title bar|state=expanded:{{GABA receptor modulators|state=expanded}}to show the template expanded, i.e., fully visible|state=autocollapse:{{GABA receptor modulators|state=autocollapse}}
If the |state= parameter in the template on this page is not set, the template's initial visibility is taken from the |default= parameter in the Collapsible option template. For the template on this page, that currently evaluates to autocollapse.